Published in Clin Cancer Res on January 15, 2013
Mixed lineage kinase 3 mediates release of C-X-C motif ligand 10-bearing chemotactic extracellular vesicles from lipotoxic hepatocytes. Hepatology (2015) 1.48
Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region. PLoS One (2013) 0.97
Oxidative stress and hepatic Nox proteins in chronic hepatitis C and hepatocellular carcinoma. Free Radic Biol Med (2014) 0.94
Treatment of hepatitis C virus infection in the future. Clin Transl Med (2013) 0.93
Hepatitis C virus protease inhibitor-resistance mutations: our experience and review. World J Gastroenterol (2013) 0.91
Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression. Neoplasia (2014) 0.90
Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. J Nat Prod (2015) 0.83
CXCL10-Mediates Macrophage, but not Other Innate Immune Cells-Associated Inflammation in Murine Nonalcoholic Steatohepatitis. Sci Rep (2016) 0.81
The role of chemokines in hepatitis C virus-mediated liver disease. Int J Mol Sci (2014) 0.81
HCV NS5A Up-Regulates COX-2 Expression via IL-8-Mediated Activation of the ERK/JNK MAPK Pathway. PLoS One (2015) 0.77
New treatments for chronic hepatitis C: an overview for paediatricians. World J Gastroenterol (2014) 0.77
Alternative splicing of human NT5E in cirrhosis and hepatocellular carcinoma produces a negative regulator of ecto-5'-nucleotidase (CD73). Mol Biol Cell (2014) 0.76
Co-expression analysis of differentially expressed genes in hepatitis C virus-induced hepatocellular carcinoma. Mol Med Rep (2014) 0.76
Engagement of Fas on Macrophages Modulates Poly I:C induced cytokine production with specific enhancement of IP-10. PLoS One (2015) 0.75
PDGFR-alpha inhibits melanoma growth via CXCL10/IP-10: a multi-omics approach. Oncotarget (2016) 0.75
Pattern recognition receptors and inflammation. Cell (2010) 21.05
Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med (2010) 13.33
Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med (2011) 12.09
Mechanisms of hepatic fibrogenesis. Gastroenterology (2008) 11.98
Regulating intracellular antiviral defense and permissiveness to hepatitis C virus RNA replication through a cellular RNA helicase, RIG-I. J Virol (2005) 9.11
Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. Proc Natl Acad Sci U S A (2005) 6.64
Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature (2008) 6.25
Toll-like receptor and RIG-I-like receptor signaling. Ann N Y Acad Sci (2008) 5.95
A road map for those who don't know JAK-STAT. Science (2002) 5.67
Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. Proc Natl Acad Sci U S A (2005) 5.64
Projecting future complications of chronic hepatitis C in the United States. Liver Transpl (2003) 3.84
An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4. J Exp Med (2003) 2.91
Dysfunction and functional restoration of HCV-specific CD8 responses in chronic hepatitis C virus infection. Hepatology (2007) 2.78
CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis (2010) 2.72
Chemokine and chemokine receptor interactions provide a mechanism for selective T cell recruitment to specific liver compartments within hepatitis C-infected liver. J Immunol (1999) 2.61
Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest (2010) 2.43
Hepatitis C core and nonstructural 3 proteins trigger toll-like receptor 2-mediated pathways and inflammatory activation. Gastroenterology (2004) 2.16
Human airway epithelial cells produce IP-10 (CXCL10) in vitro and in vivo upon rhinovirus infection. Am J Physiol Lung Cell Mol Physiol (2005) 2.05
Global burden of hepatitis C: considerations for healthcare providers in the United States. Clin Infect Dis (2012) 2.04
Role of toll-like receptors in changes in gene expression and NF-kappa B activation in mouse hepatocytes stimulated with lipopolysaccharide. Infect Immun (2002) 1.85
IFN-lambda: novel antiviral cytokines. J Interferon Cytokine Res (2006) 1.77
Dengue virus type 2 antagonizes IFN-alpha but not IFN-gamma antiviral effect via down-regulating Tyk2-STAT signaling in the human dendritic cell. J Immunol (2005) 1.63
Signal transduction by the chemokine receptor CXCR3: activation of Ras/ERK, Src, and phosphatidylinositol 3-kinase/Akt controls cell migration and proliferation in human vascular pericytes. J Biol Chem (2001) 1.61
Systemic and intrahepatic interferon-gamma-inducible protein 10 kDa predicts the first-phase decline in hepatitis C virus RNA and overall viral response to therapy in chronic hepatitis C. Hepatology (2010) 1.61
Update on the management and treatment of hepatitis C virus infection: recommendations from the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program Office. Am J Gastroenterol (2012) 1.55
The emerging role of CXCL10 in cancer (Review). Oncol Lett (2011) 1.54
Activation of chemokine and inflammatory cytokine response in hepatitis C virus-infected hepatocytes depends on Toll-like receptor 3 sensing of hepatitis C virus double-stranded RNA intermediates. Hepatology (2012) 1.48
Chemokines in the immunopathogenesis of hepatitis C infection. Hepatology (2009) 1.46
New insights into the antifibrotic effects of sorafenib on hepatic stellate cells and liver fibrosis. J Hepatol (2010) 1.38
HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol (2009) 1.35
Current status of novel antifibrotic therapies in patients with chronic liver disease. Therap Adv Gastroenterol (2011) 1.34
CXCR3 chemokine receptor distribution in normal and inflamed tissues: expression on activated lymphocytes, endothelial cells, and dendritic cells. Lab Invest (2001) 1.30
TNF-alpha and IFN-alpha enhance influenza-A-virus-induced chemokine gene expression in human A549 lung epithelial cells. Virology (2005) 1.29
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Health Technol Assess (2004) 1.27
IL-17 regulates CXCL1 mRNA stability via an AUUUA/tristetraprolin-independent sequence. J Immunol (2009) 1.24
CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors. J Clin Pathol (2006) 1.22
TLR7 stimulation in human plasmacytoid dendritic cells leads to the induction of early IFN-inducible genes in the absence of type I IFN. Blood (2009) 1.20
Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C. Am J Physiol Gastrointest Liver Physiol (2009) 1.17
Natural killer cells and hepatitis C: action and reaction. Gut (2010) 1.15
Toll-like receptor-stimulated non-parenchymal liver cells can regulate hepatitis C virus replication. J Hepatol (2008) 1.11
Human airway smooth muscle cells from asthmatic individuals have CXCL8 hypersecretion due to increased NF-kappa B p65, C/EBP beta, and RNA polymerase II binding to the CXCL8 promoter. J Immunol (2009) 1.05
Hepatic stellate cells primed with cytokines upregulate inflammation in response to peptidoglycan or lipoteichoic acid. Lab Invest (2006) 1.04
Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer (2012) 1.03
Modulation of the peripheral T-Cell response by CD4 mutants of hepatitis C virus: transition from a Th1 to a Th2 response. Hum Immunol (2003) 1.03
Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection. Hepatology (2013) 1.02
Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood (2010) 1.02
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
Centers for Disease Control and Prevention initiatives to prevent hepatitis C virus infection: a selective update. Clin Infect Dis (2012) 0.99
Drug safety evaluation of maraviroc for the treatment of HIV infection. Expert Opin Drug Saf (2011) 0.95
HCV-related proteins activate Kupffer cells isolated from human liver tissues. Dig Dis Sci (2010) 0.95
Expression of chemokine receptors on intrahepatic and peripheral lymphocytes in chronic hepatitis C infection: its relationship to liver inflammation. J Infect Dis (2004) 0.93
Therapeutic effects of the oriental herbal medicine Sho-saiko-to on liver cirrhosis and carcinoma. Hepatol Res (2011) 0.90
Guidelines for therapy of autoimmune liver disease. Semin Liver Dis (2007) 0.88
CD4⁺ and CD8⁺ regulatory T cells (Tregs) are elevated and display an active phenotype in patients with chronic HCV mono-infection and HIV/HCV co-infection. Scand J Immunol (2012) 0.88
Differential expression patterns of CXCR3 variants and corresponding CXC chemokines in clear cell ovarian cancers and endometriosis. Gynecol Oncol (2011) 0.87
Immunobiology of hepatocellular carcinoma. Langenbecks Arch Surg (2011) 0.84
Epidermal growth factor and estrogen act by independent pathways to additively promote the release of the angiogenic chemokine CXCL8 by breast tumor cells. Neoplasia (2011) 0.84
Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection. Hum Immunol (2011) 0.80
Telaprevir: an NS3/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother (2011) 0.79
Hepatitis C virus NS5A colocalizes with the core protein on lipid droplets and interacts with apolipoproteins. Virology (2002) 2.55
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
A crucial role for Kupffer cell-derived galectin-9 in regulation of T cell immunity in hepatitis C infection. PLoS One (2010) 1.62
Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. J Virol (2002) 1.44
Silymarin inhibits in vitro T-cell proliferation and cytokine production in hepatitis C virus infection. Gastroenterology (2009) 1.40
Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. Hepatology (2012) 1.36
Differential in vitro effects of intravenous versus oral formulations of silibinin on the HCV life cycle and inflammation. PLoS One (2011) 1.27
Hepatitis C virus-specific immune responses and quasi-species variability at baseline are associated with nonresponse to antiviral therapy during advanced hepatitis C. J Infect Dis (2006) 1.19
Expressed gene clusters associated with cellular sensitivity and resistance towards anti-viral and anti-proliferative actions of interferon. J Mol Biol (2004) 1.18
Regulation of CXCL-8 (interleukin-8) induction by double-stranded RNA signaling pathways during hepatitis C virus infection. J Virol (2006) 1.12
Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop. Hepatology (2008) 1.11
Unique features of hepatitis C virus capsid formation revealed by de novo cell-free assembly. J Virol (2004) 1.10
Effects of the hepatitis C virus core protein on innate cellular defense pathways. J Interferon Cytokine Res (2004) 1.09
Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J (2005) 1.08
Associations among clinical, immunological, and viral quasispecies measurements in advanced chronic hepatitis C. Hepatology (2005) 1.05
Hepatitis C infection and alcohol use: A dangerous mix for the liver and antiviral immunity. Alcohol Clin Exp Res (2006) 1.05
Hepatitis C virus induces oxidative stress, DNA damage and modulates the DNA repair enzyme NEIL1. J Gastroenterol Hepatol (2010) 1.03
A versatile ribosomal protein promoter-based reporter system for selective assessment of RNA stability and post-transcriptional control. RNA (2010) 0.98
Direct, interferon-independent activation of the CXCL10 promoter by NF-κB and interferon regulatory factor 3 during hepatitis C virus infection. J Virol (2013) 0.98
Silibinin inhibits hepatitis C virus entry into hepatocytes by hindering clathrin-dependent trafficking. Cell Microbiol (2013) 0.97
Naringenin inhibits the assembly and long-term production of infectious hepatitis C virus particles through a PPAR-mediated mechanism. J Hepatol (2011) 0.97
Independent, parallel pathways to CXCL10 induction in HCV-infected hepatocytes. J Hepatol (2013) 0.96
Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry (2007) 0.96
In vitro toxicity assessment of amphiphillic polymer-coated CdSe/ZnS quantum dots in two human liver cell models. ACS Nano (2012) 0.91
Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. Virol J (2006) 0.89
Relationships between hepatitis C virus replication and CXCL-8 production in vitro. J Virol (2006) 0.89
Stability of CXCL-8 and related AU-rich mRNAs in the context of hepatitis C virus replication in vitro. J Infect Dis (2006) 0.88
Enhanced bioactivity of silybin B methylation products. Bioorg Med Chem (2012) 0.87
Analysis of hepatitis C virus resistance to silibinin in vitro and in vivo points to a novel mechanism involving nonstructural protein 4B. Hepatology (2013) 0.86
Silibinin inhibits HIV-1 infection by reducing cellular activation and proliferation. PLoS One (2012) 0.86
Hepatitis C virus-host interactions: the NS5A protein and the interferon/chemokine systems. J Interferon Cytokine Res (2002) 0.83
Silymarin Suppresses Cellular Inflammation By Inducing Reparative Stress Signaling. J Nat Prod (2015) 0.83
Semisynthesis, cytotoxicity, antiviral activity, and drug interaction liability of 7-O-methylated analogues of flavonolignans from milk thistle. Bioorg Med Chem (2013) 0.82
Engulfment of apoptotic cells expressing HCV proteins leads to differential chemokine expression and STAT signaling in human dendritic cells. Hepatology (2007) 0.79
Arbidol inhibits viral entry by interfering with clathrin-dependent trafficking. Antiviral Res (2013) 0.79
Antiviral effects of silymarin against hepatitis C: the jury is still out. Hepatology (2008) 0.78
HCV research 20 years after discovery: a summary of the 16th international symposium on hepatitis C virus and related viruses. Gastroenterology (2009) 0.77
Functional characterization of core genes from patients with acute hepatitis C virus infection. J Infect Dis (2010) 0.76
The circulatory orbit of micro-RNAs in hepatitis C. Hepatology (2013) 0.75
Enantioselective synthesis, stereochemical correction, and biological investigation of the rodgersinine family of 1,4-benzodioxane neolignans. Org Lett (2015) 0.75
Detection of hepatitis C virus RNA in normal cervical smears. Clin Infect Dis (2003) 0.75